Joy Duemke: Optimizing Stem Cell Collection for Gene Therapy Success
Joy Duemke, Director of Marketing and Commercialization in North America at Terumo Blood and Cell Technologies, shared a post on LinkedIn:
“Gene therapy is creating new possibilities for patients with genetic hemoglobinopathies, but collecting sufficient, high-quality hematopoietic progenitor cells (HPCs) can be particularly challenging due to the impact of the underlying disease on mobilization.
Optimizing these procedures is an important step in helping more patients benefit from these therapies.
We appreciate AABB and presenting faculty, including Dr. John Manis, behind ‘Optimizing Apheresis Starting Material Collections for Stem Cell Gene Therapy Manufacturing for Patients with Genetic Hemoglobinopathies’ for tackling these challenges head-on to help ensure more SCD and thalassemia patients can benefit from these breakthrough therapies.
Register for the program on Wednesday, August 12, from 2:00–3:00 PM ET.”
Stay updated with Hemostasis Today.
-
Oct 17, 2026, 12:21Jalen Hurts Sidelined by a Superficial Blood Clot: What to Know
-
Oct 17, 2026, 09:33Robert Lookstein: Mechanical Thrombectomy Shows Functional Benefits in Intermediate-High-Risk PE
-
Oct 17, 2026, 09:18Sarra Hmidi: Tunisia Highlights Thrombosis Prevention on World Thrombosis Day
-
Oct 17, 2026, 09:05Addressing the Hidden Burden of Bleeding Disorders in Women – Hemophilia Society Mumbai Chapter
-
Oct 17, 2026, 08:49Maria Magnusson: Karolinska Experts Explore Gene Therapy in Sickle Cell Disease and Hemophilia
-
Oct 17, 2026, 04:07Weihao Li: Global HEPATIC Registry Findings on Post-Transplant Arterial Thrombosis
-
Oct 17, 2026, 03:56Ghaith Abu-Zeinah: ASH Publishes 2026 Guidelines for Myelofibrosis Management in Blood Advances
-
Oct 17, 2026, 03:48Tristan Siokos: Why Vascular Occlusion Is More Than Just Clots – Breakdown of the 8 Pathways
-
Oct 17, 2026, 02:36Archil Jaliashvili: Oxygen Transport in Capillaries